Related Experiment Video

Updated: Jun 24, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis

Angelo Zullo1, Cesare Hassan, Alessandro Andriani

  • 1Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Via E Morosini 30, 00153 Rome, Italy. zullo66@yahoo.it

Medical Oncology (Northwood, London, England)
|March 25, 2009
PubMed

Insights

For gastric MALT-lymphoma resistant to Helicobacter pylori eradication, radiotherapy shows higher remission rates than chemotherapy. This systematic review suggests radiotherapy as a suitable treatment option.

Area of Science:

  • Gastroenterology
  • Oncology
  • Hematology

Background:

  • The optimal treatment for gastric mucosa-associated lymphoid tissue (MALT) lymphoma unresponsive to Helicobacter pylori eradication is not well-defined.
  • Lack of official guidelines and randomized studies necessitates further investigation into therapeutic strategies.

Purpose of the Study:

  • To systematically review and evaluate the efficacy of various therapeutic approaches for gastric MALT-lymphoma after failed H. pylori eradication.
  • To identify the most favorable treatment strategy based on pooled patient data.

Main Methods:

  • Systematic literature review of studies involving gastric MALT-lymphoma patients.
  • Analysis of data from 315 patients who received different therapeutic interventions.
  • Comparison of remission rates across different treatment modalities (radiotherapy, surgery, chemotherapy, combination therapy).

Main Results:

  • Overall lymphoma remission was achieved in 90.1% of patients after the first therapeutic attempt.
  • Radiotherapy demonstrated a significantly higher remission rate compared to chemotherapy (97.3% vs. 85.3%, P = 0.007).
  • Remission rates for radiotherapy and surgery were comparable (97.3% vs. 92.5%, P = 0.2), with no significant difference between single and combined therapies.

Conclusions:

  • Radiotherapy appears to be the most suitable treatment for gastric MALT-lymphoma refractory to H. pylori eradication.
  • This pooled-data analysis provides valuable insights into effective oncologic approaches for this patient group.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.